Inflammatix02.17.22
Inflammatix has welcomed Kian Beyzavi, Ph.D., to its Board of Directors.
“I’m thrilled to join the board. Inflammatix is poised to address important unmet needs in the diagnosis of acute illness, which will result in improved treatment decisions and outcomes," Dr. Beyzavi said. "I look forward to working with this innovative team as they bring their breakthrough technologies to market.”
Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis and delivery of care. Since starting her career at McKinsey & Company, she has spent more than 25 years as a venture investor, entrepreneur, consultant, and general manager at Rho Ventures, Cubit Software, Medtronic, Abbott Diabetes Care, and Novartis Diagnostics. Through her work with multiple stakeholders, Dr. Beyzavi has developed a systems-level view of the complex healthcare ecosystem.
For the past 10 years Dr. Beyzavi has led a specialized consulting firm advising Fortune 500 companies, startups and others in the areas of strategy, product development, business model innovation, commercialization, and monetization of novel opportunities across life sciences. She is currently a venture partner at Cota Capital, a multistage investment firm.
“We are delighted to welcome Kian to the board. She brings a wealth of vision and deep commercialization experience across diagnostics to her new role with the company. We are drawn to her commitment to leverage technology in improving healthcare and are eager to tap into her insights as we utilize AI and genomics in our mission to improve the diagnosis of infection,” said Inflammatix CEO and Co-Founder Timothy Sweeney, M.D., Ph.D.
Inflammatix is a molecular diagnostics company whose initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. The Burlingame, CA-based company is funded by leading medical technology investors including Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures, and others.
“I’m thrilled to join the board. Inflammatix is poised to address important unmet needs in the diagnosis of acute illness, which will result in improved treatment decisions and outcomes," Dr. Beyzavi said. "I look forward to working with this innovative team as they bring their breakthrough technologies to market.”
Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis and delivery of care. Since starting her career at McKinsey & Company, she has spent more than 25 years as a venture investor, entrepreneur, consultant, and general manager at Rho Ventures, Cubit Software, Medtronic, Abbott Diabetes Care, and Novartis Diagnostics. Through her work with multiple stakeholders, Dr. Beyzavi has developed a systems-level view of the complex healthcare ecosystem.
For the past 10 years Dr. Beyzavi has led a specialized consulting firm advising Fortune 500 companies, startups and others in the areas of strategy, product development, business model innovation, commercialization, and monetization of novel opportunities across life sciences. She is currently a venture partner at Cota Capital, a multistage investment firm.
“We are delighted to welcome Kian to the board. She brings a wealth of vision and deep commercialization experience across diagnostics to her new role with the company. We are drawn to her commitment to leverage technology in improving healthcare and are eager to tap into her insights as we utilize AI and genomics in our mission to improve the diagnosis of infection,” said Inflammatix CEO and Co-Founder Timothy Sweeney, M.D., Ph.D.
Inflammatix is a molecular diagnostics company whose initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. The Burlingame, CA-based company is funded by leading medical technology investors including Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures, and others.